Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.96 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.69 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.69 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.69 |
| ▸ | F10 | P00742 | 3/20 | 0.61 |
| ▸ | F2 | P00734 | 7/20 | 0.57 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | C1S | P09871 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078620 | 0.98 | LOXL2 (1.00) | LOXL2PRSS1PRSS2PRSS3F10 | |
| Guanidine SCHEMBL29065391 | 0.83 | LOXL2 (0.67) | LOXL2F10 | |
| SCHEMBL24358796 | 0.82 | PRSS1 (0.71) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL8542393 | 0.82 | PRSS1 (1.00) | LOXL2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL28555629 | 0.80 | PRSS1 (0.74) | LOXL2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL28253026 | 0.80 | PRSS1 (0.74) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14714355 | 0.80 | PRSS1 (0.69) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL1696803 | 0.80 | PRSS1 (0.69) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL19527023 | 0.80 | LOXL2 (0.69) | LOXL2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL322008 | 0.79 | LOXL2 (0.95) | LOXL2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-113795249-B | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113795249-A | Pharmaceutical compounds for the treatment of complement-mediated disorders | 艾其林医药公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-3265445-B1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-107624110-B | Lysyl oxidase-like 2 inhibitors and uses thereof | 法玛克亚公司 | 2021-01-26 | — | — | CN | disclosed |
| WO-2020198062-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| CN-107624110-A | Inhibitor of lysyloxidase sample 2 and application thereof | 法玛克亚公司 | 2018-01-23 | — | — | CN | disclosed |
| EP-3265445-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| EP-2139461-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | Recepticon Aps (DK) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008113364-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | RECEPTICON APS (DK) | 2008-09-25 | — | — | WO | disclosed |
| US-20050245511-A1 | Novel compounds that inhibit tryptase activity | MORPHOCHEM AG | 2005-11-03 | — | — | US | disclosed |
| EP-1206444-B1 | COMPOUNDS THAT INHIBIT TRYPTASE ACTIVITY | MORPHOCHEM AG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020137687-A1 | Novel compounds that inhibit tryptase activity | MORPHOCHEM AG (DE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | LOXL2 726/4885PRSS1 278/4885PRSS2 1326/4885 |
| US-20020137687-A1 | Novel compounds that inhibit tryptase activity | TPSAB1, TPSB2, CMA1 | LOXL2 1348/4885PRSS1 15/4885PRSS2 27/4885 |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885PRSS1 372/4885PRSS2 358/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885PRSS1 372/4885PRSS2 358/4885 |
| US-20050245511-A1 | Novel compounds that inhibit tryptase activity | TPSB2, TPSAB1, CMA1 | LOXL2 1131/4885PRSS1 17/4885PRSS2 26/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | LOXL2 1/4885PRSS1 372/4885PRSS2 358/4885 |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, CFH, C1QBP | LOXL2 726/4885PRSS1 278/4885PRSS2 1326/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885PRSS1 372/4885PRSS2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.